{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:32:22Z","timestamp":1794274342171,"version":"4.9.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","award":["AstraZeneca United States"],"award-info":[{"award-number":["AstraZeneca United States"]}],"id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology and mortality outcomes in ATTR amyloidosis, addressing the need for a comprehensive understanding of its current global impact.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>An SLR of the literature from January 2018 to April 2023 was conducted using the Medline and Embase databases. The review followed the PRISMA guidelines. Studies evaluating populations with genotypes and phenotypes of ATTR amyloidosis\u00a0(variant and wild-type cardiomyopathy, polyneuropathy, and mixed) were included. Observational studies, systematic reviews, and meta-analyses were eligible, while reports, commentaries, clinical trials, and non-ATTR amyloidosis studies were excluded. Extracted data included prevalence, incidence, and mortality rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 1,458 studies identified, 113 met the inclusion criteria. Forty-nine studies reported on epidemiology, while 64 focused on mortality rates in cohorts of patients with ATTR amyloidosis from Europe (<jats:italic>n<\/jats:italic>\u2009=\u200916), North America (<jats:italic>n<\/jats:italic>\u2009=\u200926), Asia (<jats:italic>n<\/jats:italic>\u2009=\u20095), and Australia (<jats:italic>n<\/jats:italic>\u2009=\u20092). No studies were found that exclusively focused on ATTR amyloidosis in Africa or South America. ATTR prevalence ranged from 6.1\/million in the US to 232\/million in Portugal with very limited data on ATTR-PN. The 2-year mortality risk ranged from 10 to 30% among wild-type ATTR-CM and from 10 to 50% for variant type of ATTR-CM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This SLR demonstrated heterogeneity in ATTR epidemiology and mortality rates across global regions. Further investigation is needed to address knowledge gaps of the epidemiology and burden of ATTR, which may improve early diagnosis and management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03547-0","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T16:17:49Z","timestamp":1737044269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review"],"prefix":"10.1186","volume":"20","author":[{"given":"Diego","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Shivappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wittbrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Shridharmurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"J\u00e4rbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"3547_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"3547_CR2","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300.","journal-title":"Circulation"},{"issue":"38","key":"3547_CR3","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879\u201387.","journal-title":"Eur Heart J"},{"issue":"1","key":"3547_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","volume":"19","author":"JL Cavalcante","year":"2017","unstructured":"Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19(1):98.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"3547_CR5","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","volume":"22","author":"C Nitsche","year":"2020","unstructured":"Nitsche C, Aschauer S, Kammerlander AA, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22(10):1852\u201362.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"3547_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77(2):128\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3547_CR7","doi-asserted-by":"publisher","first-page":"e010358","DOI":"10.1161\/CIRCIMAGING.119.010358","volume":"13","author":"S Oda","year":"2020","unstructured":"Oda S, Kidoh M, Takashio S, et al. Quantification of myocardial extracellular volume with planning computed tomography for transcatheter aortic valve replacement to identify occult cardiac amyloidosis in patients with severe aortic stenosis. Circ Cardiovasc Imaging. 2020;13(5):e010358.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"3547_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ejhf.1974","volume":"23","author":"H Rosenblum","year":"2021","unstructured":"Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):250\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"29","key":"3547_CR9","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","volume":"41","author":"PR Scully","year":"2020","unstructured":"Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759\u201367.","journal-title":"Eur Heart J"},{"issue":"8","key":"3547_CR10","doi-asserted-by":"publisher","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","volume":"9","author":"TA Treibel","year":"2016","unstructured":"Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9(8):e005066.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"3547_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(11):1267\u201374.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"3547_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","volume":"20","author":"C Rapezzi","year":"2015","unstructured":"Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20(2):117\u201324.","journal-title":"Heart Fail Rev"},{"issue":"7 Suppl","key":"3547_CR13","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107\u201312.","journal-title":"Am J Manag Care"},{"issue":"sup1","key":"3547_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/13506129.2017.1292903","volume":"24","author":"H Schmidt","year":"2017","unstructured":"Schmidt H, Cruz MW, Botteman MF, et al. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid. 2017;24(sup1):111\u20132.","journal-title":"Amyloid"},{"issue":"2","key":"3547_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.amjcard.2011.03.040","volume":"108","author":"MD Benson","year":"2011","unstructured":"Benson MD, Teague SD, Kovacs R, et al. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108(2):285\u20139.","journal-title":"Am J Cardiol"},{"key":"3547_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.20517\/2574-1209.2021.106","volume":"6","author":"C Marco","year":"2022","unstructured":"Marco C, Pier Filippo V, Aldostefano P, et al. Cardiac amyloidosis: a changing epidemiology with open challenges. Vessel Plus. 2022;6:30.","journal-title":"Vessel Plus"},{"issue":"8 suppl","key":"3547_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0735-1097(23)00786-6","volume":"81","author":"P Miller","year":"2023","unstructured":"Miller P, Maurer MS, Poterucha T. Socioeconomic disparities prevent equitable tafamidis access in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2023;81(8 suppl):342\u2013342.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3547_CR18","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.3390\/ijms24054655","volume":"24","author":"R Goldis","year":"2023","unstructured":"Goldis R, Kaplan B, Kukuy OL, et al. Diagnostic challenges and solutions in systemic amyloidosis. Int J Mol Sci. 2023;24(5):4655.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3547_CR19","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","volume":"24","author":"A Aimo","year":"2022","unstructured":"Aimo A, Merlo M, Porcari A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24(12):2342\u201351.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3547_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1186\/s12891-023-06853-5","volume":"24","author":"E Aldinc","year":"2023","unstructured":"Aldinc E, Campbell C, Gustafsson F, et al. Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review. BMC Musculoskelet Disord. 2023;24(1):751.","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"3547_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(9):1677\u201396.","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 1","key":"3547_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10286-019-00630-y","volume":"29","author":"A Gonzalez-Duarte","year":"2019","unstructured":"Gonzalez-Duarte A, Valdes-Ferrer SI, Cantu-Brito C. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review. Clin Auton Res. 2019;29(Suppl 1):1\u20139.","journal-title":"Clin Auton Res"},{"issue":"3","key":"3547_CR23","first-page":"102","volume":"12","author":"M Magdi","year":"2022","unstructured":"Magdi M, Mostafa MR, Abusnina W, et al. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2022;12(3):102\u201311.","journal-title":"Am J Cardiovasc Dis"},{"key":"3547_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3547_CR25","doi-asserted-by":"crossref","unstructured":"Brown D, Vera-Llonch M, Perez JTO et al. Use of commercial claims data to estimate transthyretin-amyloid cardiomyopathy prevalence and incidence in the US. J Am Coll Cardiol. 2021;77(18 suppl 1).","DOI":"10.1016\/S0735-1097(21)02243-9"},{"issue":"4","key":"3547_CR26","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/ehf2.13961","volume":"9","author":"R Lauppe","year":"2022","unstructured":"Lauppe R, Liseth Hansen J, Fornwall A, et al. Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the nordic countries. ESC Heart Fail. 2022;9(4):2528\u201337.","journal-title":"ESC Heart Fail"},{"key":"3547_CR27","doi-asserted-by":"crossref","unstructured":"Lauppe RE, Liseth Hansen J, Gerdeskold C et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021;8(2).","DOI":"10.1136\/openhrt-2021-001755"},{"issue":"3\u20134","key":"3547_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000490553","volume":"51","author":"M In\u00eas","year":"2018","unstructured":"In\u00eas M, Coelho T, Concei\u00e7\u00e3o I, et al. Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study. Neuroepidemiology. 2018;51(3\u20134):177\u201382.","journal-title":"Neuroepidemiology"},{"issue":"suppl 1","key":"3547_CR29","first-page":"3131","volume":"42","author":"T Damy","year":"2021","unstructured":"Damy T, Bourel G, Slama M, et al. Epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France, a study based on the Systeme National Des Donnees De Sante (SNDS) the French nationwide claims database. Eur Heart J. 2021;42(suppl 1):3131.","journal-title":"Eur Heart J"},{"issue":"1","key":"3547_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jjcc.2022.01.002","volume":"80","author":"S Takashio","year":"2022","unstructured":"Takashio S, Tokitsu T, Matsukawa M, et al. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: the Kumamoto Cardiac Amyloidosis Survey. J Cardiol. 2022;80(1):49\u201355.","journal-title":"J Cardiol"},{"issue":"3","key":"3547_CR31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s12350-020-02098-0","volume":"27","author":"T Asif","year":"2020","unstructured":"Asif T, Araujo T, Singh V, et al. High prevalence of heart failure with reduced ejection fraction in patients with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2020;27(3):1044\u20136.","journal-title":"J Nucl Cardiol"},{"key":"3547_CR32","doi-asserted-by":"publisher","first-page":"A10590","DOI":"10.1161\/circ.146.suppl_1.10590","volume":"146","author":"M Beles","year":"2022","unstructured":"Beles M, Hens D, Masuy I, et al. Abstract 10590: detection of cardiac ATTR amyloidosis in a real-world HF population by natural language processing guided automated data extraction from electronic health records. Circulation. 2022;146:A10590.","journal-title":"Circulation"},{"issue":"4","key":"3547_CR33","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/ehf2.13360","volume":"8","author":"A Devesa","year":"2021","unstructured":"Devesa A, Camblor Blasco A, Pello Lazaro AM, et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail. 2021;8(4):2856\u201365.","journal-title":"ESC Heart Fail"},{"issue":"S2","key":"3547_CR34","first-page":"23","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Garcia-Pinilla JM, Tarilonte P. Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study [Abstracts of heart failure 2021 and the World Congress on Acute Heart failure, 29 June\u20131 July 2021]. Eur J Heart Fail. 2021;23(S2):23.","journal-title":"Eur J Heart Fail"},{"key":"3547_CR35","first-page":"A24","volume":"106","author":"G Giblin","year":"2020","unstructured":"Giblin G, Gray A, Murphy L, et al. 35 observational study to determine the prevalence of transthyretin amyloidosis in an undifferentiated heart failure with preserved ejection fraction population. BMJ Heart. 2020;106:A24.","journal-title":"BMJ Heart"},{"issue":"7","key":"3547_CR36","doi-asserted-by":"publisher","first-page":"e0254104","DOI":"10.1371\/journal.pone.0254104","volume":"16","author":"S Goland","year":"2021","unstructured":"Goland S, Volodarsky I, Fabricant Y, et al. Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PLoS ONE. 2021;16(7):e0254104.","journal-title":"PLoS ONE"},{"issue":"9","key":"3547_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8(9):712\u201324.","journal-title":"JACC Heart Fail"},{"issue":"suppl 3","key":"3547_CR38","first-page":"A11","volume":"108","author":"L Healy","year":"2022","unstructured":"Healy L, Giblin G, O\u2019Sullivan D, et al. 12 prevalence of transthyretin amyloid cardiomyopathy (aTTR-CM) in undifferentiated HFpEF. BMJ Heart. 2022;108(suppl 3):A11.","journal-title":"BMJ Heart"},{"issue":"1","key":"3547_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","volume":"8","author":"K Lindmark","year":"2020","unstructured":"Lindmark K, Pilebro B, Sundstr\u00f6m T, et al. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2020;8(1):745\u20139.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"3547_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/HPC.0000000000000183","volume":"18","author":"S Lo Presti","year":"2019","unstructured":"Lo Presti S, Horvath SA, Mihos CG, et al. Transthyretin cardiac amyloidosis as diagnosed by 99mTc-PYP scanning in patients with acute heart failure and preserved ejection fraction. Crit Pathw Cardiol. 2019;18(4):195\u20139.","journal-title":"Crit Pathw Cardiol"},{"issue":"1","key":"3547_CR41","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1002\/hsr2.938","volume":"6","author":"Y Nagayoshi","year":"2023","unstructured":"Nagayoshi Y, Kawano H, Nishihara T, et al. Coefficient of R-R interval variations under deep breathing load in patients with wild-type transthyretin amyloid cardiomyopathy: a case-control study. Health Sci Rep. 2023;6(1):e938.","journal-title":"Health Sci Rep"},{"issue":"suppl 1","key":"3547_CR42","first-page":"A12703","volume":"146","author":"A Peters","year":"2022","unstructured":"Peters A, Solomon N, Chiswell K, et al. Abstract 12703: transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: findings from GWTG-HF. Circulation. 2022;146(suppl 1):A12703.","journal-title":"Circulation"},{"issue":"S2","key":"3547_CR43","first-page":"320","volume":"23","author":"R Rocio Ruiz Hueso","year":"2021","unstructured":"Rocio Ruiz Hueso R, Bravo Candela I, Calvo Moron C, et al. Prevalence of cardiac amyloidosis in internal medicine patients with heart failure. [Abstracts of heart failure 2021 and the World Congress on Acute Heart failure, 29 June\u20131 July 2021]. Eur J Heart Fail. 2021;23(S2):320.","journal-title":"Eur J Heart Fail"},{"key":"3547_CR44","first-page":"659","volume":"61","author":"S Bukhari","year":"2020","unstructured":"Bukhari S, Brownell A, Nieves R, et al. Clinical predictors of positive Tc-99m pyrophosphate scan in patients hospitalized for decompensated heart failure. J Nucl Med. 2020;61:659.","journal-title":"J Nucl Med"},{"key":"3547_CR45","unstructured":"Gannon NP, Ward CM. Results of implementation of amyloidosis screening for patients undergoing carpal tunnel release. J Hand Surg Am. 2023 Jan 14."},{"key":"3547_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","volume":"329","author":"PF Vianello","year":"2021","unstructured":"Vianello PF, La Malfa G, Tini G, et al. Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study. Int J Cardiol. 2021;329:144\u20137.","journal-title":"Int J Cardiol"},{"key":"3547_CR47","doi-asserted-by":"crossref","unstructured":"Fukuzawa S. Cardiac amyloidosis in patients undergoing aortic valve replacement for aortic stenosis. Abstract presented at: the 3I role of metabolic imaging: ischemia, infection and inflammation. ESC Congress 2020; September 1 2020.","DOI":"10.1093\/ehjci\/ehaa946.0273"},{"issue":"suppl C","key":"3547_CR48","first-page":"C178","volume":"24","author":"G Gallone","year":"2022","unstructured":"Gallone G, Bongiovanni F, Bruno F, et al. P316 transthyretin cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a single center experience. Eur Heart J Suppl. 2022;24(suppl C):C178.","journal-title":"Eur Heart J Suppl"},{"issue":"9 suppl","key":"3547_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S0735-1097(22)01713-2","volume":"79","author":"Z Morton","year":"2022","unstructured":"Morton Z, Taylor W, Jorgensen JP, et al. Incidence and predictors of cardiac amyloidosis in the transcatheter aortic valve replacement population. J Am Coll Cardiol. 2022;79(9 suppl):722\u2013722.","journal-title":"J Am Coll Cardiol"},{"issue":"20 suppl 3","key":"3547_CR50","first-page":"A12963","volume":"142","author":"Y Muto","year":"2020","unstructured":"Muto Y, Yoshihisa A, Oikawa M, et al. Abstract 12963: the prevalence and predictors of transthyretin amyloidosis in patients underwent transcatheter aortic valve implantation. Circulation. 2020;142(20 suppl 3):A12963.","journal-title":"Circulation"},{"issue":"4","key":"3547_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","volume":"3","author":"AK Singal","year":"2021","unstructured":"Singal AK, Bansal R, Singh A, et al. Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study. JACC CardioOncol. 2021;3(4):565\u201376.","journal-title":"JACC CardioOncol"},{"issue":"S2","key":"3547_CR52","first-page":"87","volume":"24","author":"C Goena","year":"2022","unstructured":"Goena C, Arana X, Villanueva I, et al. Predictor score of diagnosis of cardiac transthyretin amyloidosis [Abstracts of heart failure 2022 and the World Congress on Acute Heart failure, 21\u201324 May 2022]. Eur J Heart Fail. 2022;24(S2):87.","journal-title":"Eur J Heart Fail"},{"key":"3547_CR53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijcard.2022.12.048","volume":"374","author":"M Prasad","year":"2023","unstructured":"Prasad M, Kim M, Chandrashekar P, et al. Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women. Int J Cardiol. 2023;374:116\u20139.","journal-title":"Int J Cardiol"},{"key":"3547_CR54","doi-asserted-by":"crossref","unstructured":"Saito M, Nakao Y, Inoue K et al. Exploration of electrocardiographic and echocardiographic findings to screen transthyretin amyloid cardiomyopathy in patients with mild left ventricular hypertrophy. Eur Heart J. 2021;42(suppl 1).","DOI":"10.1093\/eurheartj\/ehab724.010"},{"issue":"suppl 1","key":"3547_CR55","first-page":"S218","volume":"43","author":"V Di Stefano","year":"2022","unstructured":"Di Stefano V, Gagliardo A, Lupica A, et al. Hereditary transthyretin amyloidosis in the neurologic clinic: when should we think about it? The results from 24 months of systematic screening. Neurol Sci. 2022;43(suppl 1):S218. Abstracts of the 52nd Annual Conference of the Italian Society of Neurology.","journal-title":"Neurol Sci"},{"issue":"1","key":"3547_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/ajt.16216","volume":"21","author":"A Grande-Trillo","year":"2021","unstructured":"Grande-Trillo A, Baliellas C, Llado L, et al. Transthyretin amyloidosis with cardiomyopathy after domino liver transplantation: results of a cross-sectional study. Am J Transpl. 2021;21(1):372\u201381.","journal-title":"Am J Transpl"},{"key":"3547_CR57","doi-asserted-by":"crossref","unstructured":"Akers TE, Lynch K. Retrospective evaluation of suspected Vs. confirmed transthyretin amyloid cardiomyopathy (ATTR-CM) cases. J Card Fail. 2022 2022\/04\/01\/;28(5, Supplement):S110.","DOI":"10.1016\/j.cardfail.2022.03.281"},{"key":"3547_CR58","doi-asserted-by":"crossref","unstructured":"Manning D, Butler T, Butler M et al. Estimated population prevalence of cardiac transthyretin amyloidosis in elderly men derived from incidental cardiac uptake from routine bone scans \u2013 we\u2019re going to need a bigger boat. Eur Heart J. 2020;41(Supplement_2).","DOI":"10.1093\/ehjci\/ehaa946.1008"},{"issue":"5","key":"3547_CR59","doi-asserted-by":"publisher","first-page":"101106","DOI":"10.1016\/j.cpcardiol.2022.101106","volume":"48","author":"A Joury","year":"2023","unstructured":"Joury A, Faaborg-Andersen C, Quintana RA, et al. Diagnostic tools for cardiac amyloidosis: a pragmatic comparison of pathology, imaging and laboratories. Curr Probl Cardiol. 2023;48(5):101106.","journal-title":"Curr Probl Cardiol"},{"issue":"12","key":"3547_CR60","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","volume":"18","author":"DF Hutt","year":"2017","unstructured":"Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18(12):1344\u201350.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"3547_CR61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1536\/ihj.18-345","volume":"60","author":"HM Kim","year":"2019","unstructured":"Kim HM, Sohn DW, Paeng JC. Prevalence of positive 99 mTc-DPD scintigraphy as an indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly. Int Heart J. 2019;60(3):643\u20137.","journal-title":"Int Heart J"},{"issue":"24","key":"3547_CR62","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/eurheartj\/ehad281","volume":"44","author":"S Dorbala","year":"2023","unstructured":"Dorbala S. Expanding indications for non-biopsy diagnosis of transthyretin amyloid cardiomyopathy. Eur Heart J. 2023;44(24):2199\u2013201.","journal-title":"Eur Heart J"},{"key":"3547_CR63","doi-asserted-by":"crossref","unstructured":"Grogan M, Wright RS. Decreasing door-to-diagnosis time in cardiac amyloidosis: a simple one-stop shop approach. Mayo Clin Proc. 2023;98(1):7\u201310.","DOI":"10.1016\/j.mayocp.2022.11.011"},{"issue":"1","key":"3547_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141\u201359.","journal-title":"Cardiol Ther"},{"key":"3547_CR65","unstructured":"Administration USFaD. Rare Diseases at FDA 2022 [22 Feb 2024]. Available from: https:\/\/www.fda.gov\/patients\/rare-diseases-fda"},{"key":"3547_CR66","unstructured":"European Commission HaFSD-G. Orphan medicinal products 2024 [22 Feb 2024]. Available from: https:\/\/health.ec.europa.eu\/medicinal-products\/orphan-medicinal-products_en"},{"key":"3547_CR67","doi-asserted-by":"crossref","unstructured":"Fumagalli C, Zampieri M, Perfetto F et al. Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis. Mayo Clin Proc. 2021;96(8):2185\u20132191.","DOI":"10.1016\/j.mayocp.2021.04.021"},{"issue":"22","key":"3547_CR68","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146(22):1657\u201370.","journal-title":"Circulation"},{"key":"3547_CR69","doi-asserted-by":"publisher","first-page":"1146725","DOI":"10.3389\/fcvm.2023.1146725","volume":"10","author":"AG Caponetti","year":"2023","unstructured":"Caponetti AG, Accietto A, Saturi G, et al. Screening approaches to cardiac amyloidosis in different clinical settings: current practice and future perspectives. Front Cardiovasc Med. 2023;10:1146725.","journal-title":"Front Cardiovasc Med"},{"issue":"5\u20136","key":"3547_CR70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1024\/1661-8157\/a004001","volume":"112","author":"OM Galuszka","year":"2023","unstructured":"Galuszka OM, Stampfli SF. Red flags suggesting cardiac transthyretin amyloidosis (ATTR) in clinical practice. Praxis (Bern 1994). 2023;112(5\u20136):357\u201361.","journal-title":"Praxis (Bern 1994)"},{"issue":"17","key":"3547_CR71","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","volume":"27","author":"G Vergaro","year":"2020","unstructured":"Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020;27(17):1806\u201315.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"3547_CR72","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1007\/s10072-023-06859-w","volume":"44","author":"JK van der Warendorf","year":"2023","unstructured":"van der Warendorf JK, Dooijes D, et al. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy. Neurol Sci. 2023;44(10):3679\u201385.","journal-title":"Neurol Sci"},{"issue":"3","key":"3547_CR73","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/ehf2.13884","volume":"9","author":"K Bay","year":"2022","unstructured":"Bay K, Gustafsson F, Maiborg M, et al. Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review. ESC Heart Fail. 2022;9(3):1524\u201341.","journal-title":"ESC Heart Fail"},{"issue":"8","key":"3547_CR74","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ejhf.2504","volume":"24","author":"M Merlo","year":"2022","unstructured":"Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail. 2022;24(8):1377\u201386.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3547_CR75","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","volume":"18","author":"L Gentile","year":"2023","unstructured":"Gentile L, Coelho T, Dispenzieri A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18(1):350. 2023\/11\/10.","journal-title":"Orphanet J Rare Dis"},{"key":"3547_CR76","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.amjcard.2022.10.039","volume":"187","author":"LR Mitrani","year":"2023","unstructured":"Mitrani LR, Tumasian RA 3rd, Vilches S, et al. Racial differences in atrial fibrillation management between white patients and black patients in transthyretin cardiac amyloid. Am J Cardiol. 2023;187:164\u201370.","journal-title":"Am J Cardiol"},{"key":"3547_CR77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.amjcard.2022.11.014","volume":"190","author":"A Basdavanos","year":"2023","unstructured":"Basdavanos A, Maurer MS, Ives L, et al. Prevalence of orthopedic manifestations in patients with cardiac amyloidosis with a focus on shoulder pathologies. Am J Cardiol. 2023;190:67\u201374.","journal-title":"Am J Cardiol"},{"key":"3547_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","volume":"67","author":"AS Manolis","year":"2019","unstructured":"Manolis AS, Manolis AA, Manolis TA, et al. Cardiac amyloidosis: an underdiagnosed\/underappreciated disease. Eur J Intern Med. 2019;67:1\u201313.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"3547_CR79","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12350-022-03044-y","volume":"30","author":"GB Grossman","year":"2023","unstructured":"Grossman GB. Quantitation in ATTR cardiac amyloidosis: the next step is almost there! J Nucl Cardiol. 2023;30(1):140\u20133.","journal-title":"J Nucl Cardiol"},{"key":"3547_CR80","doi-asserted-by":"crossref","unstructured":"Yan CL, Thakkar Rivera N, Hoffman J. Inappropriate use of technetium-99m pyrophosphate scanning for the evaluation of transthyretin amyloidosis [Letter]. Amyloid. 2023 Oct;6:1\u20133.","DOI":"10.1080\/13506129.2023.2267162"},{"issue":"9 suppl","key":"3547_CR81","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0735-1097(22)01297-9","volume":"79","author":"S Amaka","year":"2022","unstructured":"Amaka S, Bhattacharya PT, Maurer MS, et al. Tafamidis effectiveness in wild-type transthyretin cardiac amyloidosis by mayo staging. J Am Coll Cardiol. 2022;79(9 suppl):306.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3547_CR82","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ejhf.2028","volume":"23","author":"M B\u00e9zard","year":"2021","unstructured":"B\u00e9zard M, Kharoubi M, Galat A, et al. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail. 2021;23(2):264\u201374.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"3547_CR83","doi-asserted-by":"publisher","first-page":"101358","DOI":"10.1016\/j.cpcardiol.2022.101358","volume":"47","author":"K Hussain","year":"2022","unstructured":"Hussain K, Macrinici V, Wathen L, et al. Impact of tafamidis on survival in a real-world community-based cohort. Curr Probl Cardiol. 2022;47(12):101358.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"3547_CR84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","volume":"13","author":"J Gonz\u00e1lez-Moreno","year":"2024","unstructured":"Gonz\u00e1lez-Moreno J, Dispenzieri A, Grogan M, et al. Clinical and genotype characteristics and Symptom Migration in patients with mixed phenotype transthyretin amyloidosis from the Transthyretin Amyloidosis outcomes Survey. Cardiol Therapy. 2024;13(1):117\u201335. 2024\/03\/01.","journal-title":"Cardiol Therapy"},{"issue":"5","key":"3547_CR85","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3547_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-9-29","volume":"9","author":"JB Rein\u00e9s","year":"2014","unstructured":"Rein\u00e9s JB, Vera TR, Mart\u00edn MU, et al. Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Ll\u00e0tzer Hospital descriptive study. Orphanet J Rare Dis. 2014;9(1):29. 2014\/02\/26.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3547_CR87","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cardfail.2022.10.394","volume":"29","author":"M Longoni","year":"2023","unstructured":"Longoni M, Ward A, Bhasin K, et al. Underutilization of guideline-directed genetic testing in cardiomyopathies: a missed opportunity. J Card Fail. 2023;29(4):704\u20135.","journal-title":"J Card Fail"},{"issue":"1","key":"3547_CR88","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ehf2.14188","volume":"10","author":"S Dobner","year":"2023","unstructured":"Dobner S, Bernhard B, Asatryan B, et al. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023;10(1):397\u2013404.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"3547_CR89","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.hlc.2022.01.006","volume":"31","author":"M Harapoz","year":"2022","unstructured":"Harapoz M, Evans S, Geenty P, et al. Correlation of quantitative 99mTc DPD scintigraphy with echocardiographic alterations in left atrial parameters in transthyretin amyloidosis. Heart Lung Circ. 2022;31(6):804\u201314.","journal-title":"Heart Lung Circ"},{"key":"3547_CR90","doi-asserted-by":"crossref","unstructured":"Oghina S, Josse C, Bezard M et al. Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment. J Clin Med. 2021;10(21).","DOI":"10.3390\/jcm10214868"},{"issue":"12","key":"3547_CR91","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","volume":"24","author":"RK Patel","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis. Eur J Heart Fail. 2022;24(12):2355\u201363.","journal-title":"Eur J Heart Fail"},{"issue":"suppl K","key":"3547_CR92","first-page":"K237","volume":"24","author":"A Porcari","year":"2022","unstructured":"Porcari A, Razvi Y, Masi A, et al. 185 prevalence, disease characteristics and outcomes of hereditary transthyretin amyloid cardiomyopathy among elderly individuals. Eur Heart J Suppl. 2022;24(suppl K):K237.","journal-title":"Eur Heart J Suppl"},{"issue":"2","key":"3547_CR93","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11739-022-03125-3","volume":"18","author":"MV Silverii","year":"2023","unstructured":"Silverii MV, Argiro A, Baldasseroni S, et al. Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis. Intern Emerg Med. 2023;18(2):585\u201393.","journal-title":"Intern Emerg Med"},{"issue":"suppl G","key":"3547_CR94","first-page":"G169","volume":"23","author":"G Trimarchi","year":"2021","unstructured":"Trimarchi G, Perna A, Zampieri M, et al. 516 prevalence of carpal tunnel syndrome in patients with transthyretin cardiac amyloidosis. Eur Heart J Suppl. 2021;23(suppl G):G169.","journal-title":"Eur Heart J Suppl"},{"key":"3547_CR95","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.amjcard.2022.06.048","volume":"180","author":"L Trujillo","year":"2022","unstructured":"Trujillo L, Colombo R. Hereditary transthyretin amyloidosis cardiomyopathy: the South Florida experience. Am J Cardiol. 2022;180:140\u20138.","journal-title":"Am J Cardiol"},{"issue":"11 suppl 1","key":"3547_CR96","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S0735-1097(20)31713-7","volume":"75","author":"AF Ali","year":"2020","unstructured":"Ali AF, Hussain M, Hanna M, et al. Lack of impact of aortic stenosis on mortality in patients with transthyretin cardiac amyloidosis (attr). J Am Coll Cardiol. 2020;75(11 suppl 1):1086.","journal-title":"J Am Coll Cardiol"},{"issue":"9 suppl","key":"3547_CR97","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0735-1097(22)01298-0","volume":"79","author":"J Amadio","year":"2022","unstructured":"Amadio J, Dispenzieri A, Jimenez FL, et al. Prognostic value of an artificial intelligence enhanced ecg model in cardiac amyloidosis. J Am Coll Cardiol. 2022;79(9 suppl):307.","journal-title":"J Am Coll Cardiol"},{"key":"3547_CR98","unstructured":"Arana X, Goena C, Villanueva I et al. Prognostic impact of diagnosis of transthyretin cardiac amyloidosis. Eur J Heart Fail.24:71."},{"issue":"1","key":"3547_CR99","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","volume":"15","author":"F Bandera","year":"2022","unstructured":"Bandera F, Martone R, Chacko L, et al. Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. JACC Cardiovasc Imaging. 2022;15(1):17\u201329.","journal-title":"JACC Cardiovasc Imaging"},{"key":"3547_CR100","doi-asserted-by":"crossref","unstructured":"Bhattacharya PT, Teruya SL, De Los Santos J et al. Heart failure with reduced ejection fraction: an under-appreciated clinical phenotype of transthyretin cardiac amyloid (ATTR-CA). J Card Fail. 2022 2022\/04\/01\/;28(5 suppl):S35\u20136.","DOI":"10.1016\/j.cardfail.2022.03.095"},{"key":"3547_CR101","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/circ.142.suppl_3.16145","volume":"142","author":"S Bukhari","year":"2020","unstructured":"Bukhari S, Bashir Z, Shpilsky D, et al. Abstract 16145: reduced ejection fraction at diagnosis is an independent predictor of mortality in transthyretin amyloid cardiomyopathy. Circulation. 2020;142:142.","journal-title":"Circulation"},{"issue":"10","key":"3547_CR102","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1016\/j.cardfail.2020.09.468","volume":"26","author":"SR Bustillo","year":"2020","unstructured":"Bustillo SR, Coca JMM, More SV, et al. Transthyretin cardiac amyloidosis: patient characteristics in our region. J Card Fail. 2020;26(10):S163.","journal-title":"J Card Fail"},{"issue":"14","key":"3547_CR103","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439\u201347.","journal-title":"Eur Heart J"},{"issue":"11","key":"3547_CR104","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.cardfail.2021.06.022","volume":"27","author":"T Dalia","year":"2021","unstructured":"Dalia T, Acharya P, Chan WC, et al. Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Card Fail. 2021;27(11):1285\u20139.","journal-title":"J Card Fail"},{"issue":"9","key":"3547_CR105","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Hanna M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol. 2020;6(9):1118\u201327.","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"3547_CR106","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/europace\/euz314","volume":"22","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni O, Kanj M, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace. 2020;22(2):259\u201364.","journal-title":"Europace"},{"issue":"2","key":"3547_CR107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13506129.2019.1698417","volume":"27","author":"E Driggin","year":"2020","unstructured":"Driggin E, Helmke S, de Los Santos J, et al. Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype. Amyloid. 2020;27(2):73\u201380.","journal-title":"Amyloid"},{"issue":"4","key":"3547_CR108","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","volume":"4","author":"E Gonzalez-Lopez","year":"2022","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L, et al. Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol. 2022;4(4):442\u201354.","journal-title":"JACC CardioOncol"},{"issue":"4","key":"3547_CR109","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00392-020-01801-y","volume":"110","author":"S Hein","year":"2021","unstructured":"Hein S, Furkel J, Knoll M, et al. Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. Clin Res Cardiol. 2021;110(4):579\u201390.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"3547_CR110","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ehf2.14262","volume":"10","author":"IA Hoerbrand","year":"2023","unstructured":"Hoerbrand IA, Volz MJ, Aus dem Siepen F, et al. Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis. ESC Heart Fail. 2023;10(2):1003\u201312.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"3547_CR111","doi-asserted-by":"publisher","first-page":"e013829","DOI":"10.1161\/CIRCIMAGING.121.013829","volume":"15","author":"M Hussain","year":"2022","unstructured":"Hussain M, Krywanczyk A, Donnellan E, et al. Association between atrial uptake on cardiac scintigraphy with technetium-99m-pyrophosphate labeled bone-seeking tracers and atrial fibrillation. Circ Cardiovasc Imaging. 2022;15(5):e013829.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"3547_CR112","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13023-022-02425-3","volume":"17","author":"SC Jang","year":"2022","unstructured":"Jang SC, Nam JH, Lee SA, et al. Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis. Orphanet J Rare Dis. 2022;17(1):262.","journal-title":"Orphanet J Rare Dis"},{"issue":"S1","key":"3547_CR113","first-page":"405","volume":"27","author":"L Leon Cejas","year":"2020","unstructured":"Leon Cejas L, Calandra C, Conti ME, et al. Argentinean study in transthyretin familial amyloid polyneuropathy. An old illness that we need to think. Eur J Neurol. 2020;27(S1):405.","journal-title":"Eur J Neurol"},{"key":"3547_CR114","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jval.2020.04.168","volume":"23","author":"J Nativi-Nicolau","year":"2020","unstructured":"Nativi-Nicolau J, Vieira MC, Fischer N, et al. PCV65 hospitalizations and mortality among cardiac amyloidosis patients covered by medicare advantage. Value Health. 2020;23:S102\u20133.","journal-title":"Value Health"},{"issue":"suppl 3","key":"3547_CR115","first-page":"A16164","volume":"142","author":"L Rashdan","year":"2020","unstructured":"Rashdan L, Chandrashekar P, Dale Z, et al. Abstract 16164: left ventricular ejection fraction matters in transthyretin amyloidosis cardiomyopathy. Circulation. 2020;142(suppl 3):A16164.","journal-title":"Circulation"},{"issue":"suppl 1","key":"3547_CR116","first-page":"S31","volume":"26","author":"S Righetto","year":"2021","unstructured":"Righetto S, Pilichou K, Salvalaggio A, et al. Identification of subclinical transthyretin-related amyloidosis with bone scintigraphy in 9616 patients. J Peripher Nerv Syst. 2021;26(suppl 1):S31.","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"3547_CR117","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1007\/s12350-022-02961-2","volume":"29","author":"A Salvalaggio","year":"2022","unstructured":"Salvalaggio A, Cipriani A, Righetto S, et al. Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies. J Nucl Cardiol. 2022;29(6):3419\u201325.","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"3547_CR118","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1002\/ehf2.13667","volume":"8","author":"S Shimoni","year":"2021","unstructured":"Shimoni S, Zikri M, Haberman D, et al. Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival. ESC Heart Fail. 2021;8(6):4549\u201361.","journal-title":"ESC Heart Fail"},{"key":"3547_CR119","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.1016\/j.jval.2020.08.498","volume":"23","author":"M Slama","year":"2020","unstructured":"Slama M, Charron P, Algalarrondo V, et al. PCV7 Development of an algorithm using the dispensed daily doses of LOOP diuretics to assess survival of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) according to the disease severity. Value Health. 2020;23:S487.","journal-title":"Value Health"},{"issue":"2 Pt 1","key":"3547_CR120","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","volume":"11","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Vranian MN, Tower-Rader A, et al. Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):234\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"3547_CR121","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.hlc.2021.11.018","volume":"31","author":"V Uusitalo","year":"2022","unstructured":"Uusitalo V, Suomalainen O, Loimaala A, et al. Prognostic value of 99mTc-HMDP scintigraphy in elderly patients with chronic heart failure. Heart Lung Circ. 2022;31(5):629\u201337.","journal-title":"Heart Lung Circ"},{"issue":"4","key":"3547_CR122","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s12350-016-0768-9","volume":"25","author":"MN Vranian","year":"2018","unstructured":"Vranian MN, Sperry BW, Hanna M, et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes. J Nucl Cardiol. 2018;25(4):1247\u201356.","journal-title":"J Nucl Cardiol"},{"key":"3547_CR123","doi-asserted-by":"crossref","unstructured":"Zhang K, Zhang R, Deych E et al. Global longitudinal strain is prognostic in light chain and transthyretin cardiac amyloidosis while the apical sparing ratio of longitudinal strain is not. J Am Coll Cardiol. 2020 2020\/03\/24;75(11):1657.","DOI":"10.1016\/S0735-1097(20)32284-1"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03547-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:25:01Z","timestamp":1737048301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03547-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3547"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03547-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FD, FM and DS are full-time employees of Evidera. DD received consulting fees and speakers\u2019 honoraria from Akcea, Alnylam, Pfizer and AstraZeneca. NS, EW, and KJ are full-time employees of AstraZeneca and hold stock in the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}